|
US4433059A
(en)
|
1981-09-08 |
1984-02-21 |
Ortho Diagnostic Systems Inc. |
Double antibody conjugate
|
|
US4444878A
(en)
|
1981-12-21 |
1984-04-24 |
Boston Biomedical Research Institute, Inc. |
Bispecific antibody determinants
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4851332A
(en)
|
1985-04-01 |
1989-07-25 |
Sloan-Kettering Institute For Cancer Research |
Choriocarcinoma monoclonal antibodies and antibody panels
|
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
US5869620A
(en)
|
1986-09-02 |
1999-02-09 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
|
JPH021556A
(en)
|
1988-06-09 |
1990-01-05 |
Snow Brand Milk Prod Co Ltd |
Hybrid antibody and production thereof
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
|
US5399346A
(en)
|
1989-06-14 |
1995-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Gene therapy
|
|
DE3920358A1
(en)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
WO1991003493A1
(en)
|
1989-08-29 |
1991-03-21 |
The University Of Southampton |
Bi-or trispecific (fab)3 or (fab)4 conjugates
|
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
|
US5273743A
(en)
|
1990-03-09 |
1993-12-28 |
Hybritech Incorporated |
Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
|
|
GB9012995D0
(en)
|
1990-06-11 |
1990-08-01 |
Celltech Ltd |
Multivalent antigen-binding proteins
|
|
US5582996A
(en)
|
1990-12-04 |
1996-12-10 |
The Wistar Institute Of Anatomy & Biology |
Bifunctional antibodies and method of preparing same
|
|
DE69233482T2
(en)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Method for reducing the immunogenicity of antibody variable domains
|
|
DE4118120A1
(en)
|
1991-06-03 |
1992-12-10 |
Behringwerke Ag |
TETRAVALENT BISPECIFIC RECEPTORS, THEIR PRODUCTION AND USE
|
|
US6511663B1
(en)
|
1991-06-11 |
2003-01-28 |
Celltech R&D Limited |
Tri- and tetra-valent monospecific antigen-binding proteins
|
|
EP0590058B1
(en)
|
1991-06-14 |
2003-11-26 |
Genentech, Inc. |
HUMANIZED Heregulin ANTIBODy
|
|
US5637481A
(en)
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
|
ES2136092T3
(en)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
|
|
US5932448A
(en)
|
1991-11-29 |
1999-08-03 |
Protein Design Labs., Inc. |
Bispecific antibody heterodimers
|
|
WO1993011794A1
(en)
|
1991-12-13 |
1993-06-24 |
Xoma Corporation |
Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
|
|
CA2128511C
(en)
|
1992-01-23 |
2006-11-07 |
Andreas Pluckthun |
Monomeric and dimeric antibody-fragment fusion proteins
|
|
CA2372813A1
(en)
|
1992-02-06 |
1993-08-19 |
L.L. Houston |
Biosynthetic binding protein for cancer marker
|
|
GB9203459D0
(en)
|
1992-02-19 |
1992-04-08 |
Scotgen Ltd |
Antibodies with germ-line variable regions
|
|
US5646253A
(en)
|
1994-03-08 |
1997-07-08 |
Memorial Sloan-Kettering Cancer Center |
Recombinant human anti-LK26 antibodies
|
|
CA2135408A1
(en)
|
1992-05-08 |
1993-11-25 |
Peter C. Keck |
Chimeric multivalent protein analogues and methods of use thereof
|
|
US6005079A
(en)
|
1992-08-21 |
1999-12-21 |
Vrije Universiteit Brussels |
Immunoglobulins devoid of light chains
|
|
DE69334275D1
(en)
|
1992-08-21 |
2009-05-20 |
Univ Bruxelles |
Immunoglobulins without a light chain
|
|
US5350674A
(en)
|
1992-09-04 |
1994-09-27 |
Becton, Dickinson And Company |
Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
|
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
|
CA2145278C
(en)
|
1992-09-25 |
2009-03-10 |
Commonwealth Scientific And Industrial Research Organisation |
Target binding polypeptide
|
|
GB9221657D0
(en)
|
1992-10-15 |
1992-11-25 |
Scotgen Ltd |
Recombinant bispecific antibodies
|
|
CA2126967A1
(en)
|
1992-11-04 |
1994-05-11 |
Anna M. Wu |
Novel antibody construct
|
|
GB9323648D0
(en)
|
1992-11-23 |
1994-01-05 |
Zeneca Ltd |
Proteins
|
|
ATE199392T1
(en)
|
1992-12-04 |
2001-03-15 |
Medical Res Council |
MULTIVALENT AND MULTI-SPECIFIC BINDING PROTEINS, THEIR PRODUCTION AND USE
|
|
US5863755A
(en)
*
|
1993-04-21 |
1999-01-26 |
Max Planck Gessellschaft |
Nucleic acid encoding novel receptor-type phosphotyrosine phosphatase-κ
|
|
US6476198B1
(en)
|
1993-07-13 |
2002-11-05 |
The Scripps Research Institute |
Multispecific and multivalent antigen-binding polypeptide molecules
|
|
US5635602A
(en)
|
1993-08-13 |
1997-06-03 |
The Regents Of The University Of California |
Design and synthesis of bispecific DNA-antibody conjugates
|
|
WO1995009917A1
(en)
|
1993-10-07 |
1995-04-13 |
The Regents Of The University Of California |
Genetically engineered bispecific tetravalent antibodies
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
US5786464C1
(en)
|
1994-09-19 |
2012-04-24 |
Gen Hospital Corp |
Overexpression of mammalian and viral proteins
|
|
JP3659261B2
(en)
|
1994-10-20 |
2005-06-15 |
モルフォシス・アクチェンゲゼルシャフト |
Targeted heterojunction of a recombinant protein to a multifunctional complex
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
|
WO1996037621A2
(en)
|
1995-05-23 |
1996-11-28 |
Morphosys Gesellschaft Für Proteinoptimierung Mbh |
Multimeric proteins
|
|
US5989830A
(en)
|
1995-10-16 |
1999-11-23 |
Unilever Patent Holdings Bv |
Bifunctional or bivalent antibody fragment analogue
|
|
US6177078B1
(en)
|
1995-12-29 |
2001-01-23 |
Medvet Science Pty Limited |
Monoclonal antibody antagonists to IL-3
|
|
WO1997025068A2
(en)
|
1996-01-05 |
1997-07-17 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Mesothelin antigen and methods and kits for targeting it
|
|
WO1997038102A1
(en)
|
1996-04-04 |
1997-10-16 |
Unilever Plc |
Multivalent and multispecific antigen-binding protein
|
|
US6114148C1
(en)
|
1996-09-20 |
2012-05-01 |
Gen Hospital Corp |
High level expression of proteins
|
|
US6365712B1
(en)
|
1996-10-25 |
2002-04-02 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Methods and compositions for inhibiting inflammation and angiogenesis comprising a mammalian CD97 α subunit
|
|
US6323322B1
(en)
|
1997-04-30 |
2001-11-27 |
Enzon, Inc. |
Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
|
|
US20030207346A1
(en)
|
1997-05-02 |
2003-11-06 |
William R. Arathoon |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
US20020062010A1
(en)
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
AU736707B2
(en)
|
1997-06-11 |
2001-08-02 |
Anaphore, Inc. |
Trimerising module
|
|
JP3614866B2
(en)
|
1997-06-12 |
2005-01-26 |
リサーチ コーポレイション テクノロジーズ,インコーポレイティド |
Artificial antibody polypeptide
|
|
DK1027439T3
(en)
|
1997-10-27 |
2010-05-10 |
Bac Ip Bv |
Multivalent antigen-binding proteins
|
|
DE69833459T2
(en)
|
1997-12-01 |
2006-08-17 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
ANTIBODIES, FV MOLECULES, AND IMMUNOCONJUGATES HAVING HIGH BINDING SAFFINITY FOR MESOTHELIN AND METHODS FOR THEIR USE
|
|
EP1049787B1
(en)
|
1998-01-23 |
2004-11-24 |
Vlaams Interuniversitair Instituut voor Biotechnologie |
Multipurpose antibody derivatives
|
|
HUP9900956A2
(en)
|
1998-04-09 |
2002-04-29 |
Aventis Pharma Deutschland Gmbh. |
Single-chain multiple antigen-binding molecules, their preparation and use
|
|
DE19819846B4
(en)
|
1998-05-05 |
2016-11-24 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Multivalent antibody constructs
|
|
GB9812545D0
(en)
|
1998-06-10 |
1998-08-05 |
Celltech Therapeutics Ltd |
Biological products
|
|
ES2207278T3
(en)
|
1998-07-28 |
2004-05-16 |
Micromet Ag |
HETEROMINICBODIES.
|
|
WO2000023600A1
(en)
|
1998-10-19 |
2000-04-27 |
Ariad Gene Therapeutics, Inc. |
Materials and methods involving conditional aggregation domains
|
|
EP1144655A2
(en)
|
1998-10-19 |
2001-10-17 |
Ariad Gene Therapeutics, Inc. |
Regulated expression using conditional er retention domains
|
|
US6333396B1
(en)
|
1998-10-20 |
2001-12-25 |
Enzon, Inc. |
Method for targeted delivery of nucleic acids
|
|
US7527787B2
(en)
|
2005-10-19 |
2009-05-05 |
Ibc Pharmaceuticals, Inc. |
Multivalent immunoglobulin-based bioactive assemblies
|
|
US7534866B2
(en)
|
2005-10-19 |
2009-05-19 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
|
EP1235842A4
(en)
|
1999-10-15 |
2003-04-23 |
Univ Massachusetts |
GENESIS OF THE RNA INTERFERENCE PATH AS AID OF TARGETED GENTIAN INTERFERENCE
|
|
US6326193B1
(en)
|
1999-11-05 |
2001-12-04 |
Cambria Biosciences, Llc |
Insect control agent
|
|
US7262005B1
(en)
*
|
2000-02-04 |
2007-08-28 |
Aurora Biosciences Corporation |
Methods of protein destabilization and uses thereof
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
HK1052372A1
(en)
|
2000-02-24 |
2003-09-11 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
ATE510855T1
(en)
|
2000-03-06 |
2011-06-15 |
Univ Kentucky Res Found |
USE OF AN ANTIBODIES OR AN IMMUNOTOXIN THAT RESPECTIVELY THAT SELECTIVELY BINDS TO CD123 TO IMPAIR HEMATOLOGICAL CANCER PROGENIC CELLS
|
|
PT2857516T
(en)
|
2000-04-11 |
2017-08-28 |
Genentech Inc |
Multivalent antibodies and uses therefor
|
|
AU2001264946A1
(en)
|
2000-05-24 |
2001-12-03 |
Imclone Systems Incorporated |
Bispecific immunoglobulin-like antigen binding proteins and method of production
|
|
WO2001096584A2
(en)
|
2000-06-12 |
2001-12-20 |
Akkadix Corporation |
Materials and methods for the control of nematodes
|
|
AU2001270609A1
(en)
|
2000-06-30 |
2002-01-14 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
Heterodimeric fusion proteins
|
|
EP1309705B1
(en)
|
2000-07-25 |
2012-02-15 |
Immunomedics Inc. |
Multivalent target binding protein
|
|
CN1308447C
(en)
|
2000-10-20 |
2007-04-04 |
中外制药株式会社 |
Low molecular weight agonist antibody
|
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
|
WO2002072635A2
(en)
|
2001-03-13 |
2002-09-19 |
University College London |
Specific binding members
|
|
CN1294148C
(en)
|
2001-04-11 |
2007-01-10 |
中国科学院遗传与发育生物学研究所 |
Single-stranded cyctic trispecific antibody
|
|
JP4303105B2
(en)
|
2001-06-28 |
2009-07-29 |
ドマンティス リミテッド |
Dual specific ligands and their use
|
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
|
AU2002319544B2
(en)
|
2001-08-10 |
2008-07-10 |
Aberdeen University |
Antigen binding domains from fish
|
|
ATE346866T1
(en)
|
2001-09-14 |
2006-12-15 |
Affimed Therapeutics Ag |
MULTIMERIC, SINGLE CHAIN, TANDEM FV ANTIBODIES
|
|
US20030211078A1
(en)
|
2001-12-07 |
2003-11-13 |
Heavner George A. |
Pseudo-antibody constructs
|
|
US7745140B2
(en)
|
2002-01-03 |
2010-06-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
|
|
US20040018557A1
(en)
|
2002-03-01 |
2004-01-29 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
|
EP1500665B1
(en)
|
2002-04-15 |
2011-06-15 |
Chugai Seiyaku Kabushiki Kaisha |
METHODS FOR CONSTRUCTING scDb LIBRARIES
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
GB0230203D0
(en)
|
2002-12-27 |
2003-02-05 |
Domantis Ltd |
Fc fusion
|
|
GB0305702D0
(en)
|
2003-03-12 |
2003-04-16 |
Univ Birmingham |
Bispecific antibodies
|
|
WO2004087758A2
(en)
|
2003-03-26 |
2004-10-14 |
Neopharm, Inc. |
Il 13 receptor alpha 2 antibody and methods of use
|
|
US20050003403A1
(en)
|
2003-04-22 |
2005-01-06 |
Rossi Edmund A. |
Polyvalent protein complex
|
|
US7700097B2
(en)
|
2003-06-27 |
2010-04-20 |
Biogen Idec Ma Inc. |
Purification and preferential synthesis of binding molecules
|
|
CA2531118C
(en)
|
2003-07-01 |
2013-01-08 |
Immunomedics, Inc. |
Multivalent carriers of bi-specific antibodies
|
|
US7696322B2
(en)
|
2003-07-28 |
2010-04-13 |
Catalent Pharma Solutions, Inc. |
Fusion antibodies
|
|
CA2534659A1
(en)
|
2003-08-05 |
2005-02-17 |
Morphotek, Inc. |
A variant cell surface molecule associated with cancer
|
|
EP1660186B1
(en)
|
2003-08-18 |
2013-12-25 |
MedImmune, LLC |
Humanization of antibodies
|
|
US20050042664A1
(en)
|
2003-08-22 |
2005-02-24 |
Medimmune, Inc. |
Humanization of antibodies
|
|
JPWO2005035586A1
(en)
|
2003-10-08 |
2007-11-22 |
協和醗酵工業株式会社 |
Fusion protein composition
|
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
|
WO2005062916A2
(en)
|
2003-12-22 |
2005-07-14 |
Centocor, Inc. |
Methods for generating multimeric molecules
|
|
GB0329825D0
(en)
|
2003-12-23 |
2004-01-28 |
Celltech R&D Ltd |
Biological products
|
|
US20050266425A1
(en)
|
2003-12-31 |
2005-12-01 |
Vaccinex, Inc. |
Methods for producing and identifying multispecific antibodies
|
|
US8383575B2
(en)
|
2004-01-30 |
2013-02-26 |
Paul Scherrer Institut |
(DI)barnase-barstar complexes
|
|
WO2005098043A2
(en)
*
|
2004-03-30 |
2005-10-20 |
The President And Fellows Of Harvard College |
Ligand-dependent protein splicing
|
|
AU2005250408B2
(en)
|
2004-05-27 |
2010-09-23 |
The Trustees Of The University Of Pennsylvania |
Novel artificial antigen presenting cells and uses therefor
|
|
EP1786918A4
(en)
|
2004-07-17 |
2009-02-11 |
Imclone Systems Inc |
Novel tetravalent bispecific antibody
|
|
WO2006028936A2
(en)
|
2004-09-02 |
2006-03-16 |
Genentech, Inc. |
Heteromultimeric molecules
|
|
EP2322560B1
(en)
|
2005-03-10 |
2013-09-04 |
Morphotek, Inc. |
Anti-mesothelin antibodies
|
|
KR101374454B1
(en)
|
2005-03-31 |
2014-03-17 |
추가이 세이야쿠 가부시키가이샤 |
Methods for producing polypeptides by regulating polypeptide association
|
|
CA2604032C
(en)
|
2005-04-06 |
2017-08-22 |
Ibc Pharmaceuticals, Inc. |
Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
|
|
JP5838021B2
(en)
|
2005-04-15 |
2015-12-24 |
マクロジェニクス,インコーポレーテッド |
Covalently bonded diabody and its use
|
|
US20060263367A1
(en)
|
2005-05-23 |
2006-11-23 |
Fey Georg H |
Bispecific antibody devoid of Fc region and method of treatment using same
|
|
EP1726650A1
(en)
|
2005-05-27 |
2006-11-29 |
Universitätsklinikum Freiburg |
Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
|
|
KR20140053410A
(en)
|
2005-08-19 |
2014-05-07 |
아보트 러보러터리즈 |
Dual variable domain immunoglobulin and uses thereof
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
EP1757622B1
(en)
|
2005-08-26 |
2009-12-23 |
PLS Design GmbH |
Bivalent IgY antibody constructs for diagnostic and therapeutic applications
|
|
WO2007044887A2
(en)
|
2005-10-11 |
2007-04-19 |
Transtarget, Inc. |
Method for producing a population of homogenous tetravalent bispecific antibodies
|
|
EP1962961B1
(en)
|
2005-11-29 |
2013-01-09 |
The University Of Sydney |
Demibodies: dimerisation-activated therapeutic agents
|
|
CA2638794A1
(en)
|
2006-02-15 |
2007-08-23 |
Imclone Systems Incorporated |
Functional antibodies
|
|
EA015992B1
(en)
|
2006-03-17 |
2012-01-30 |
Байоджен Айдек Эмэй Инк. |
Stabilized antibody and multivalent antibinding molecule based thereon, methods for making thereof and use such stabilized antibody
|
|
ATE509033T1
(en)
|
2006-03-20 |
2011-05-15 |
Univ California |
ENGINEERED ANTI-PROSTATE STEM CELL ANTIGEN (PSCA) ANTIBODIES FOR CANCER TARGETING
|
|
WO2007112362A2
(en)
|
2006-03-24 |
2007-10-04 |
The Regents Of The University Of California |
Construction of a multivalent scfv through alkyne-azide 1,3-dipolar cycloaddition
|
|
DK1999154T3
(en)
|
2006-03-24 |
2012-12-03 |
Merck Patent Gmbh |
MANUFACTURED HETERODIMERED PROTEIN DOMAINS
|
|
JP5144499B2
(en)
|
2006-03-31 |
2013-02-13 |
中外製薬株式会社 |
Antibody modification method for purifying bispecific antibodies
|
|
TWI395754B
(en)
|
2006-04-24 |
2013-05-11 |
Amgen Inc |
Humanized c-kit antibody
|
|
EP2799449A1
(en)
|
2006-05-25 |
2014-11-05 |
Bayer Intellectual Property GmbH |
Dimeric molecular complexes
|
|
US20070274985A1
(en)
|
2006-05-26 |
2007-11-29 |
Stefan Dubel |
Antibody
|
|
CN105837690A
(en)
|
2006-06-12 |
2016-08-10 |
新兴产品开发西雅图有限公司 |
Single-chain multivalent binding proteins with effector function
|
|
AU2007285763B2
(en)
|
2006-08-18 |
2011-12-15 |
Armagen Technologies, Inc. |
Agents for blood-brain barrier delivery
|
|
EP2471816A1
(en)
|
2006-08-30 |
2012-07-04 |
Genentech, Inc. |
Multispecific antibodies
|
|
JP2010505775A
(en)
|
2006-10-04 |
2010-02-25 |
クーベンハヴンス・ユニヴェルシテット |
Production of cancer-specific immune response against MUC1 and cancer-specific MUC1 antibody
|
|
FR2906808B1
(en)
|
2006-10-10 |
2012-10-05 |
Univ Nantes |
USE OF MONOCLONAL ANTIBODIES SPECIFIC TO THE O-ACETYLATED FORMS OF GANGLIOSIDE GD2 IN THE TREATMENT OF CERTAIN CANCERS
|
|
WO2008140477A2
(en)
|
2006-11-02 |
2008-11-20 |
Capon Daniel J |
Hybrid immunoglobulins with moving parts
|
|
US8173792B2
(en)
*
|
2007-02-09 |
2012-05-08 |
The Board Of Trustees Of The Leland Stanford Junior University |
Method for regulating protein function in cells using synthetic small molecules
|
|
WO2008103645A2
(en)
|
2007-02-19 |
2008-08-28 |
Wisconsin Alumni Research Foundation |
Prostate cancer and melanoma antigens
|
|
EP2626372B1
(en)
|
2007-03-29 |
2018-03-21 |
Genmab A/S |
Bispecific antibodies and methods for production thereof
|
|
WO2008127735A1
(en)
|
2007-04-13 |
2008-10-23 |
Stemline Therapeutics, Inc. |
Il3ralpha antibody conjugates and uses thereof
|
|
CA2682605A1
(en)
|
2007-04-18 |
2008-10-30 |
Zymogenetics, Inc. |
Single chain fc, methods of making and methods of treatment
|
|
JP2010190572A
(en)
|
2007-06-01 |
2010-09-02 |
Sapporo Medical Univ |
Antibody directed against il13ra2, and diagnostic/therapeutic agent comprising the antibody
|
|
CN101952312A
(en)
|
2007-07-31 |
2011-01-19 |
米迪缪尼有限公司 |
Multispecific epitope binding proteins and uses thereof
|
|
CA2696263C
(en)
|
2007-08-15 |
2017-06-13 |
Bing Liu |
Monospecific and multispecific antibodies and method of use
|
|
HRP20150074T1
(en)
|
2007-10-01 |
2015-03-13 |
Bristol-Myers Squibb Company |
Human antibodies that bind mesothelin, and uses thereof
|
|
KR101559599B1
(en)
|
2007-11-26 |
2015-10-12 |
바이엘 인텔렉쳐 프로퍼티 게엠베하 |
Anti-mesothelin antibodies and uses therefor
|
|
CA2706425A1
(en)
|
2007-11-27 |
2009-06-04 |
Ablynx N.V. |
Method for obtaining polypeptide constructs comprising two or more single domain antibodies
|
|
TW200944231A
(en)
|
2007-11-30 |
2009-11-01 |
Glaxo Group Ltd |
Antigen-binding constructs
|
|
US8242247B2
(en)
|
2007-12-21 |
2012-08-14 |
Hoffmann-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
US8227577B2
(en)
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
|
EP3663318A1
(en)
|
2008-01-07 |
2020-06-10 |
Amgen Inc. |
Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
|
|
US9067986B2
(en)
|
2009-04-27 |
2015-06-30 |
Oncomed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
|
ES2550639T3
(en)
|
2009-04-27 |
2015-11-11 |
Kyowa Hakko Kirin Co., Ltd. |
Anti-IL-3Ralpha antibody for use in the treatment of a blood tumor
|
|
IT1398927B1
(en)
*
|
2009-06-25 |
2013-03-28 |
Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi |
BACTERIAL EXPRESSION OF AN ARTIFICIAL GENE FOR THE PRODUCTION OF CRM197 AND DERIVATIVES.
|
|
US8956828B2
(en)
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
CA3040276A1
(en)
|
2009-12-02 |
2011-06-09 |
Imaginab, Inc. |
J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
|
|
CN105777907B
(en)
|
2010-02-24 |
2020-03-17 |
伊缪诺金公司 |
Folate receptor 1 antibodies and immunoconjugates and uses thereof
|
|
PT2560993T
(en)
|
2010-04-20 |
2024-09-16 |
Genmab As |
FC HETERODIMERIC ANTIBODY CONTAINING PROTEINS AND METHODS FOR THEIR PRODUCTION
|
|
US9242014B2
(en)
|
2010-06-15 |
2016-01-26 |
The Regents Of The University Of California |
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
|
|
NZ603581A
(en)
|
2010-06-19 |
2015-05-29 |
Sloan Kettering Inst Cancer |
Anti-gd2 antibodies
|
|
CA2805442C
(en)
|
2010-07-21 |
2020-05-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of an hla locus
|
|
EP3115373B1
(en)
*
|
2010-09-08 |
2019-08-28 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus |
Chimeric antigen receptors with an optimized hinge region
|
|
EP2614143B1
(en)
|
2010-09-08 |
2018-11-07 |
Baylor College Of Medicine |
Immunotherapy of non-small lung cancer using genetically engineered gd2-specific t cells
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
EP3459560B1
(en)
|
2011-04-08 |
2021-02-24 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
|
|
AR086044A1
(en)
|
2011-05-12 |
2013-11-13 |
Imclone Llc |
ANTIBODIES THAT SPECIFICALLY JOIN A C-KIT EXTRACELLULAR DOMAIN AND USES OF THE SAME
|
|
EP2714737A1
(en)
|
2011-05-27 |
2014-04-09 |
Glaxo Group Limited |
Bcma (cd269/tnfrsf17) -binding proteins
|
|
TWI570240B
(en)
*
|
2011-09-09 |
2017-02-11 |
默沙東公司 |
Conditional replication CMV as a cellular giant virus vaccine
|
|
KR20140060541A
(en)
|
2011-09-16 |
2014-05-20 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
Rna engineered t cells for the treatment of cancer
|
|
EP3692794A1
(en)
|
2011-09-16 |
2020-08-12 |
Baylor College of Medicine |
Targeting the tumor microenvironment using manipulated nkt cells
|
|
ITMO20110270A1
(en)
|
2011-10-25 |
2013-04-26 |
Sara Caldrer |
A MODELED EFFECTIVE CELL FOR THE TREATMENT OF NEOPLASIES EXPRESSING THE DISIALONGANGLIOSIDE GD2
|
|
IN2014CN03887A
(en)
|
2011-10-27 |
2015-10-16 |
Genmab As |
|
|
US9272002B2
(en)
|
2011-10-28 |
2016-03-01 |
The Trustees Of The University Of Pennsylvania |
Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
|
|
WO2013074916A1
(en)
|
2011-11-18 |
2013-05-23 |
Board Of Regents, The University Of Texas System |
Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
|
|
US9439768B2
(en)
|
2011-12-08 |
2016-09-13 |
Imds Llc |
Glenoid vault fixation
|
|
EP2814846B1
(en)
|
2012-02-13 |
2020-01-08 |
Seattle Children's Hospital d/b/a Seattle Children's Research Institute |
Bispecific chimeric antigen receptors and therapeutic uses thereof
|
|
CA3285826A1
(en)
|
2012-02-22 |
2026-03-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
|
|
WO2013151664A1
(en)
*
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of proteins
|
|
CA2868121C
(en)
|
2012-03-23 |
2021-06-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
|
WO2013151649A1
(en)
|
2012-04-04 |
2013-10-10 |
Sialix Inc |
Glycan-interacting compounds
|
|
EP2850106B1
(en)
|
2012-05-18 |
2022-03-23 |
Aptevo Research and Development LLC |
Bispecific scfv immunofusion (bif) binding to cd123 and cd3
|
|
ES2728782T3
(en)
|
2012-05-25 |
2019-10-28 |
Univ California |
Methods and compositions for RNA-directed target DNA modification and for RNA-directed transcription modulation
|
|
WO2013192294A1
(en)
|
2012-06-20 |
2013-12-27 |
Boston 3T Biotechnologies, Inc. |
Cellular therapies for treating and preventing cancers and other immune system disorders
|
|
MX382772B
(en)
*
|
2012-07-13 |
2025-03-11 |
Univ Pennsylvania |
COMPOSITION FOR USE TO PREVENT OR DELAY TRANSPLANT REJECTION OF A TRANSPLANTED TISSUE OR ORGAN IN A SUBJECT.
|
|
LT2884999T
(en)
|
2012-08-20 |
2021-04-12 |
Fred Hutchinson Cancer Research Center |
Method and compositions for cellular immunotherapy
|
|
WO2014043189A1
(en)
*
|
2012-09-14 |
2014-03-20 |
The Regents Of The University Of Colorado, A Body Corporate |
Conditionally replication deficient herpes viruses and use thereof in vaccines
|
|
WO2014055442A2
(en)
|
2012-10-01 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting stromal cells for the treatment of cancer
|
|
US10117896B2
(en)
|
2012-10-05 |
2018-11-06 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
|
TW201425336A
(en)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
BCMA antigen binding proteins
|
|
CN105209621B
(en)
|
2012-12-12 |
2021-05-25 |
布罗德研究所有限公司 |
Engineering and Optimization of Improved Systems, Methods and Enzyme Compositions for Sequence Manipulation
|
|
KR102955556B1
(en)
|
2012-12-12 |
2026-04-22 |
더 브로드 인스티튜트, 인코퍼레이티드 |
Crispr-cas component systems, methods and compositions for sequence manipulation
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
JP6636803B2
(en)
|
2013-02-05 |
2020-01-29 |
エンクマフ エスアーエールエル |
Method for selection of antibodies to BCMA
|
|
WO2014130635A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
|
|
SG11201505896YA
(en)
|
2013-02-20 |
2015-09-29 |
Novartis Ag |
Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
|
|
WO2014138805A1
(en)
|
2013-03-14 |
2014-09-18 |
Csl Limited |
Anti il-3r alpha agents and uses thereof
|
|
US20160046718A1
(en)
|
2013-03-14 |
2016-02-18 |
Csl Limited |
Agents that neutralize il-3 signalling and uses thereof
|
|
US9657105B2
(en)
|
2013-03-15 |
2017-05-23 |
City Of Hope |
CD123-specific chimeric antigen receptor redirected T cells and methods of their use
|
|
AR095374A1
(en)
|
2013-03-15 |
2015-10-14 |
Amgen Res Munich Gmbh |
UNION MOLECULES FOR BCMA AND CD3
|
|
ES2769574T3
(en)
|
2013-03-15 |
2020-06-26 |
Michael C Milone |
Recognition of cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
UY35468A
(en)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER
|
|
ES2918501T3
(en)
|
2013-12-19 |
2022-07-18 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
|
EP3114217A4
(en)
*
|
2014-03-07 |
2017-09-20 |
Bellicum Pharmaceuticals, Inc. |
Caspase polypeptides having modified activity and uses thereof
|
|
CN122399016A
(en)
|
2014-03-15 |
2026-07-17 |
诺华股份有限公司 |
Treatment of cancer using chimeric antigen receptor
|
|
SG10202109752XA
(en)
|
2014-04-07 |
2021-10-28 |
Novartis Ag |
Treatment of cancer using anti-cd19 chimeric antigen receptor
|
|
EP3166968B1
(en)
*
|
2014-05-02 |
2021-09-22 |
The Trustees of the University of Pennsylvania |
Compositions and methods of chimeric autoantibody receptor t cells
|
|
RS61406B1
(en)
*
|
2014-06-06 |
2021-03-31 |
Bluebird Bio Inc |
Improved t cell compositions
|
|
BR112017000939A2
(en)
|
2014-07-21 |
2017-11-14 |
Novartis Ag |
cancer treatment using a cll-1 chimeric antigen receptor
|
|
JP6831777B2
(en)
|
2014-07-21 |
2021-02-17 |
ノバルティス アーゲー |
Treatment of cancer using the CD33 chimeric antigen receptor
|
|
AU2015292744C1
(en)
|
2014-07-21 |
2021-01-21 |
Novartis Ag |
Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
|
|
EP3172231B1
(en)
|
2014-07-24 |
2021-05-05 |
Bluebird Bio, Inc. |
Bcma chimeric antigen receptors
|
|
EP3180359A1
(en)
*
|
2014-08-14 |
2017-06-21 |
Novartis AG |
Treatment of cancer using gfr alpha-4 chimeric antigen receptor
|
|
EP3712171A1
(en)
|
2014-08-19 |
2020-09-23 |
Novartis AG |
Treatment of cancer using a cd123 chimeric antigen receptor
|
|
RU2751362C2
(en)
*
|
2014-12-29 |
2021-07-13 |
Новартис Аг |
Methods for producing cells expressing chimeric antigen receptor
|
|
PL3280729T3
(en)
|
2015-04-08 |
2022-08-22 |
Novartis Ag |
Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
|
|
US10550379B2
(en)
*
|
2015-06-29 |
2020-02-04 |
The Board Of Trustees Of The Leland Stanford Junior University |
Degron fusion constructs and methods for controlling protein production
|
|
CA2994969A1
(en)
*
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
|
|
JP6894430B2
(en)
*
|
2015-08-24 |
2021-06-30 |
セレクティスCellectis |
Chimeric antigen receptor with integrated regulatory function
|
|
US20230071283A1
(en)
*
|
2016-04-15 |
2023-03-09 |
Aimee S. Payne |
Compositions and methods for selective protein expression
|